EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Calcitonin gene-related peptide receptor antagonism reduces motion sickness indicators in mouse migraine models

Shafaqat M Rahman, Anne E Luebke iD

Cephalalgia · 2024

DOI: 10.1177/03331024231223971 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cephalalgia, 2024. Verfasst von Shafaqat M Rahman und 1 weiteren Autor:innen. Beteiligte Einrichtung: University of Rochester, Department of Biomedical Engineering, Rochester, NY, USA. Hauptthemen laut MEDLINE: Migraine Disorders, Motion Sickness. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDCD NIH HHS, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Migraine and vestibular migraine are disorders associated with a heightened motion sensitivity that provoke symptoms of motion-induced nausea and motion sickness. VM affects ∼3% of adults in the USA and affects three-fold more women than men. Triptans (selective serotonin receptor agonists) relieve migraine pain but lack efficacy for vertigo. Murine models of photophobia and allodynia have used injections of calcitonin gene-related peptide (CGRP) or other migraine triggers, such as sodium nitroprusside (SNP), to induce migraine sensitivities in mice to touch and light. Yet, there is limited research on whether these triggers affect motion-induced nausea in mice, and whether migraine blockers can reduce these migraine symptoms. We hypothesized that systemic delivery of CGRP or SNP will increase motion sickness susceptibility and motion-induced nausea in mouse models, and that migraine blockers can block these changes induced by systemically delivered CGRP or SNP.

Methods

We investigated two measures of motion sickness assessment [motion sickness index (MSI) scoring and motion-induced thermoregulation] after intraperitoneal injections of either CGRP or SNP in C57BL/6J mice. The drugs olcegepant, sumatriptan and rizatriptan were used to assess the efficacy of migraine blockers.

Results

MSI measures were confounded by CGRP’s effect on gastric distress. However, analysis of tail vasodilatations as a surrogate for motion-induced nausea was robust for both migraine triggers. Only olcegepant treatment rescued tail vasodilatations.

Conclusions

These preclinical findings support the use of small molecule CGRP receptor antagonists for the treatment of motion-induced nausea of migraine, and show that triptan therapeutics are ineffective against motion-induced nausea of migraine. Trial Registration: Not Applicable

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersMotion SicknessHumansMaleAdultFemaleMiceAnimalsReceptors, Calcitonin Gene-Related PeptideCalcitonin Gene-Related PeptideMice, Inbred C57BLNausea

Stichwörter der Autor:innen

CGRPgastric distressmigrainemotion-sicknessmousenauseaolcegepantrizatriptansumatriptanvestibular

Substanzen

Receptors, Calcitonin Gene-Related PeptideCalcitonin Gene-Related Peptide

Autor:innen und Institutionen

  • University of Rochester, Department of Biomedical Engineering, Rochester, NY, USA.
  • University of Rochester Medical Center, Department of Neuroscience, Del Monte Institute of Neuroscience, Rochester, NY, USA.

ORCID-Profile: Anne E Luebke

Förderung

  • NIDCD NIH HHS
  • NIH

Zitieren

APA

Rahman, S. M., & Luebke, A. E. (2024). Calcitonin gene-related peptide receptor antagonism reduces motion sickness indicators in mouse migraine models. Cephalalgia. https://doi.org/10.1177/03331024231223971

Vancouver

Rahman SM, Luebke AE. Calcitonin gene-related peptide receptor antagonism reduces motion sickness indicators in mouse migraine models. Cephalalgia. 2024. doi:10.1177/03331024231223971

BibTeX
@article{Rahman2024,
  author = {Rahman, Shafaqat M and Luebke, Anne E},
  title = {Calcitonin gene-related peptide receptor antagonism reduces motion sickness indicators in mouse migraine models},
  journal = {Cephalalgia},
  year = {2024},
  doi = {10.1177/03331024231223971}
}
Kostenlos starten →